Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
about
Increased mortality for neurological and mental diseases following early bilateral oophorectomySurvival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriersProphylactic oophorectomy in premenopausal women and long-term healthIncreased cardiovascular mortality after early bilateral oophorectomyOophorectomy, estrogen, and dementia: a 2014 updateChallenging and complex decisions in the management of the BRCA mutation carrierOral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.Premature menopause and risk of neurological disease: basic mechanisms and clinical implicationsHormone replacement therapy after prophylactic adnexectomy.Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriersOophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunityNew strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy.Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT.Genetic epidemiology and primary care.Online tool to guide decisions for BRCA1/2 mutation carriers.Ovarian cancer rates after hysterectomy with and without salpingo-oophorectomy.Impact of risk-reducing salpingo-oophorectomy in premenopausal women.Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI ratsComparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.Management options after prophylactic surgeries in women with BRCA mutations: a review.Physicians' experiences with BRCA1/2 testing in community settingsOvarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study.Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and AgingCancer risk management decision making for BRCA+ women.Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.ESHRE Guideline: management of women with premature ovarian insufficiency.Hormone replacement therapy in young women with surgical primary ovarian insufficiency.Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review.Real-world health services utilisation and outcomes after and testing in Ontario, Canada: the What Comes Next Cohort Study protocol
P2860
Q24645015-92EC551D-7EE2-4CB5-836D-D00F6F60B9A1Q24654487-83935971-D137-4485-AD0C-9829AC48C217Q24655584-07733AC4-0C72-4BB4-8AFA-B9703C3AA59FQ24658403-3258A9DC-0BFD-41A0-A01A-985548658544Q26853730-8B3EFD73-6D9E-4516-8AFC-0BC6BE047E61Q27026559-345FFB35-1C27-420E-9620-D42A39C804D4Q30433319-D5E67DC9-0101-4A3C-81E0-DC93543D565BQ33693151-04B14210-9836-4869-B983-F3345FD82869Q33721579-DFDDBC92-D9FE-4EA8-93D9-E80241F31A53Q34126089-D5D773F9-4BB9-49DE-8BFC-84971BBAFD37Q34351382-9A95A9B5-2C13-4746-8E41-14D256790DC1Q34612492-154DE3E1-F492-42A1-B972-FFA0A41D73C4Q35021170-09E89E19-7DA5-412B-9121-E52DAD30552FQ35108393-D0666DFE-FDFC-4E3C-AA92-D41C8C7EC0B6Q35688722-A7AB4C09-B660-44A0-9BE7-E3E7FD5FBFD9Q35808372-54C2D1F5-33F7-4194-BFF6-CB30C8A17ED5Q36219581-B8699CDB-401D-43F4-ADEF-F0C990EC62B3Q36372962-669D580F-3A47-4D8D-89F5-86A9258C1A21Q36491403-538181CE-AC4F-4177-BECB-CB78D9739164Q36738628-330EB322-7921-4C31-B1DA-630E4A17CB1DQ36959824-4D0221DD-62A8-441A-AAC0-5F157A1D0203Q37103116-BC314DC1-262A-4E2F-8B4F-BB377962A63DQ37218063-34C4E644-970A-4C1E-B3DB-2331DC7DD407Q37277562-368844AD-53A8-4843-898F-37C82FD3C214Q38564191-A3DE2E87-4B96-47D5-AB83-D78F9A749416Q38599703-CF90478B-4C1A-4854-B5B7-545E14881B07Q38732720-B9D85743-CC3D-44B7-B8AF-CF9C91FF5766Q38786469-6B333CE8-CD84-4620-BB36-3708D4807FBFQ38993952-5EE17143-3BB7-48B9-9CA6-F05073D4A25AQ50091589-325081B6-DE3E-46DD-A5D1-93F8DA18D519Q58764940-CD7D889E-1728-41F3-B5B8-E03F6829BE4D
P2860
Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Hormone replacement therapy an ...... utations: a decision analysis.
@ast
Hormone replacement therapy an ...... utations: a decision analysis.
@en
Hormone replacement therapy an ...... utations: a decision analysis.
@nl
type
label
Hormone replacement therapy an ...... utations: a decision analysis.
@ast
Hormone replacement therapy an ...... utations: a decision analysis.
@en
Hormone replacement therapy an ...... utations: a decision analysis.
@nl
prefLabel
Hormone replacement therapy an ...... utations: a decision analysis.
@ast
Hormone replacement therapy an ...... utations: a decision analysis.
@en
Hormone replacement therapy an ...... utations: a decision analysis.
@nl
P2093
P356
P1476
Hormone replacement therapy an ...... utations: a decision analysis.
@en
P2093
Barbara Weber
J Sanford Schwartz
Katrina Armstrong
Stephen C Rubin
Thomas Randall
P304
P356
10.1200/JCO.2004.06.090
P407
P577
2004-02-23T00:00:00Z